# Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab

> **NCT04014374** · — · RECRUITING · sponsor: **Kyowa Kirin, Inc.** · enrollment: 150 (estimated)

## Conditions studied

- Leukemia/Lymphoma
- Cutaneous T Cell Lymphoma
- ATLL

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04014374
- **Lead sponsor:** Kyowa Kirin, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2019-09-10
- **Primary completion:** 2030-02
- **Final completion:** 2030-02
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2024-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04014374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04014374, "Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04014374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*